GRAIL, Inc.: Mixed — EPS -$2.21, Revenue $37.54M
Mixed ResultQ3 2026 · After-market
Did GRAIL, Inc. (GRAL) beat earnings today?
It was a mixed report for Q3 2026 — GRAIL, Inc. (GRAL) beat on EPS but missed on revenue.
Earnings Per Share+11.24% surprise
-$2.21Actual
Expected: -$2.49
vs. year ago +10.2%
Total Revenue-15.10% surprise
$37.53MActual
Expected: $44.21M
vs. year ago +4.0%
Released Nov 04 · 4:02 PM ET
Earning Report
| Metric | Q3 2026 | Q3 2025 | YoY Change % |
|---|---|---|---|
| Revenue | $37.53M | $36.19M | +4.0% |
| Revenue detail — reported lines | |||
| └─Screening revenue | $37.27M | $32.81M | +14.0% |
| └─Development services revenue | $266.00K | $3.39M | -92.1% |
| Net loss | ($103.57M) | ($88.98M) | -16.0% |
| Basic and Diluted EPS | -$2.21 | -$2.46 | +10.2% |
Business Highlights
- ➤FDA Advisory Committee panel delivered a favorable vote for Galleri approval.
- ➤Company anticipates an FDA decision by early Q1 2027.
- ➤Published NHS-Galleri results in *The New England Journal of Medicine* and *Nature Medicine*.
- ➤Published final PATHFINDER 2 results in *Nature Medicine*.
- ➤Studies included approximately 175,000 participants across the UK and North America.
- ➤Studies reported 4-6.5x more cancers detected with favorable safety and consistent clinical performance.
- ➤NHS-Galleri showed a >20% reduction in Stage IV diagnoses for 12 prespecified aggressive cancers.
- ➤NHS-Galleri showed a 25% reduction in cancers diagnosed after emergency presentation.
- ➤Galleri plus standard-of-care screening detected more Stage I-II cancers than the UK program found across stages.
Management Commentary
Josh Ofman, MD, MSHS, Chief Executive Officer of GRAIL
“GRAIL achieved significant milestones this quarter including a favorable vote for approval of Galleri at the FDA Advisory Committee. This achievement strengthens the foundation for Galleri as we continue on our path towards potential regulatory approval, broader access and reimbursement. We are seeing continued commercial momentum as a number of positive advancements, consistent market education, and promotional pricing initiatives gain traction.”